"Region\u00E1ln\u00ED centrum aplikovan\u00E9 molekul\u00E1rn\u00ED onkologie (RECAMO)" . . . "Hlavn\u00EDm c\u00EDlem n\u00E1dorov\u00E9ho v\u00FDzkumu a v\u00FDvoje protin\u00E1dorov\u00FDch terapeutik je selektivn\u00ED terapie, tedy jej\u00ED zam\u011B\u0159en\u00ED na n\u00E1dorov\u00E9 bu\u0148ky s minim\u00E1ln\u00EDm \u00FA\u010Dinkem na bu\u0148ky nen\u00E1dorov\u00E9. Pokro\u010Dil\u00E1 anal\u00FDza genomick\u00FDch abnormalit zodpov\u011Bdn\u00FDch za onkogenezi otev\u00EDr\u00E1 mo\u017Enosti personalizovan\u00E9 molekul\u00E1rn\u00ED terapie zalo\u017Een\u00E9 na genomu jedince. Souhrnn\u00E9 c\u00EDle: -zalo\u017Eit multidisciplin\u00E1rn\u00ED skupinu \u010Desk\u00FDch a zahrani\u010Dn\u00EDch v\u00FDzkumn\u00FDch pracovn\u00EDk\u016F a l\u00E9ka\u0159sk\u00FDch specialist\u016F pracuj\u00EDc\u00EDch v jednom centru vybaven\u00E9m nejmodern\u011Bj\u0161\u00EDmi technologiemi pro v\u00FDzkum nov\u00FDch biomarker\u016F v\u00FDznamn\u00FDch pro diagn\u00F3zu, zobrazovac\u00ED metody, monitorov\u00E1n\u00ED onemocn\u011Bn\u00ED, progn\u00F3zu a l\u00E9\u010Dbu n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED. -identifikovat nov\u00E9 biologick\u00E9 c\u00EDle, je\u017E budou vyu\u017E\u00EDv\u00E1ny v onkologick\u00E9 p\u00E9\u010Di, specificky pro zobrazovac\u00ED metody, histologick\u00E9 potvrzen\u00ED diagn\u00F3zy, stanoven\u00ED progn\u00F3zy nebo l\u00E9\u010Dby, v\u00FDvoj protin\u00E1dorov\u00E9 terapie a to za pomoci definovan\u00E9ho klinick\u00E9ho materi\u00E1lu v Bance biologick\u00E9ho materi\u00E1lu Masarykova onkologick\u00E9ho \u00FAstavu (MO\u00DA) (\u010Desk\u00E9ho n\u00E1rodn\u00EDho koordin\u00E1tora Biobanking and Biomolecular Resources Research Infrastructure - BBMRI) -prost\u0159ednictv\u00EDm kooperace v\u00FDzkumn\u00EDk\u016F a l\u00E9ka\u0159\u016F vytvo\u0159it podm\u00EDnky pro prov\u00E1d\u011Bn\u00ED preklinick\u00FDch zkou\u0161ek a klinick\u00FDch hodnocen\u00ED f\u00E1ze I -zefektivnit vyu\u017Eit\u00ED z\u00EDskan\u00FDch znalost\u00ED v aplikovan\u00E9m v\u00FDzkumu transferem poznatk\u016F do komer\u010Dn\u00ED sf\u00E9ry. -p\u0159isp\u011Bt ke zkvalitn\u011Bn\u00ED vzd\u011Bl\u00E1n\u00ED a mo\u017Enost\u00ED odborn\u00E9ho r\u016Fstu pregradu\u00E1ln\u00EDch a postgradu\u00E1ln\u00EDch student\u016F -vytvo\u0159it p\u0159\u00EDle\u017Eitosti pro zam\u011Bstn\u00E1n\u00ED a kari\u00E9rn\u00ED r\u016Fst v r\u00E1mci RECAMO a p\u0159isp\u011Bt k v\u00FDchov\u011B odborn\u00EDk\u016F pro akademick\u00FD i komer\u010Dn\u00ED sektor v regionu" . . "http://www.recamo.cz"^^ . . . . "222"^^ . . "cancer research; applied molecular oncology; personalized medicine"@en . "222"^^ . . " applied molecular oncology" . . "Regional Centre for Applied Molecular Oncology (RECAMO)"@en . . . "cancer research" . "2015-04-02+02:00"^^ . "1"^^ . . "2014-12-31+01:00"^^ . . "0"^^ . "2013-12-20+01:00"^^ . "The princip\u00E1l goal of the cancer research and activities in anticancer therapeutics development is to design a selective therapy targeted against tumour cells while minimizing side effects on non-tumour tissues. Advanced analysis of genomic abnormalities involved in carcinogenesis opens up new possibilities of personalized molecular therapies based of genome of an individual. Summary objectives: - to set up a multidisciplinary team of Czech and foreign researchers and medical specialists working in one centre equipped with the state-of-the-art technologies for new biomarker research. Such biomarkers will be important in diagnosis, disease monitoring, imaging methods and therapy. - to identify new biological targets that will be used in clinical oncology, histopathological confirmation, determination of disease prognosis and/or therapeutic efficacy and new anticancer therapy development. To accomplish this, well defined clinical biological materi\u00E1l will be used, which is banked in a Biobank of MMCI, who is also a Czech national coordinator for European biobanking infrastructure BBMRI). - through collaboration of clinicians and researchers processes and environment will be set up for performing preclinical trials and Phase I clinical trials. - to facilitate applications of applied research results through knowledge transfer to commercial applications. - to enhance quality of education of graduate and postgraduate students and to increase possibilities of their professional growth - to create opportunities for employability and career development in RECAMO and thus contribute for training of specialists for both academic and commercial spheres in this region."@en . "ED2.1.00/03.0101" . . . "0"^^ . "http://www.isvav.cz/projectDetail.do?rowId=ED2.1.00/03.0101"^^ . . "2011-01-01+01:00"^^ .